CDEK
← All drugs Report issue

apx005m

mAbexperimental

Clinical trial activity

14 trials · 27 clinical orgs · 0 marketing orgs

Phase 1
9
Phase 2
9
Phase 3
0
Phase 4
0

Earliest trial started May 1, 2015 (NCT02482168)

Timeline

2010s

  1. Jan 1, 2015

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2017

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Also known as

  • apx005m

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05201001Phase 2Sep 30, 2023Central and Eastern European Oncology Group, GSO Global Clinical Research BV, Katholieke Universiteit Leuven, Nordic Society for Gynaecologic Oncology, Nordic Society of Gynaecological Oncology - Clinical Trials Unit, Swiss Go Trial Group
NCT05419479Phase 1/Phase 2 (Phase 2)Nov 30, 2022Arcus Biosciences, Inc., Harvard University, Lustgarten Foundation
NCT04495257Phase 1Sep 14, 2020Apexigen, Inc., Yale University
NCT04130854Phase 2Apr 24, 2020Apexigen, Inc., The University of Texas, Dallas
NCT04337931Phase 2Dec 16, 2019Apexigen, Inc.
NCT03719430Phase 2Mar 20, 2019Apexigen, Inc., Columbia University
NCT03597282Phase 1Aug 31, 2018Apexigen, Inc., Neon Therapeutics
NCT03502330Phase 1Jun 9, 2018Apexigen, Inc., Bristol-Myers Squibb, National Cancer Institute (NCI), Yale University
NCT03389802Phase 1Feb 2, 2018A Kids Brain Tumor Cure, American Lebanese Syrian Associated Charities, Apexigen, Inc., Memorial Sloan-Kettering Cancer Center, National Cancer Institute (NCI), Pediatric Brain Tumor Consortium, Solving Kids’ Cancer, St. Jude Children's Hospital, Ty Louis Campbell Foundation
NCT03214250Phase 1/Phase 2 (Phase 2)Jul 21, 2017Apexigen, Inc., Bristol-Myers Squibb, Cancer Research Institute, The Parker Institute
NCT03165994Phase 2Jul 1, 2017Apexigen, Inc., University of California, San Francisco
NCT02706353Phase 1/Phase 2 (Phase 2)Jun 2, 2017Apexigen, Inc., University of Texas at Houston
NCT03123783Phase 1/Phase 2 (Phase 2)May 1, 2017Apexigen, Inc., Bristol-Myers Squibb
NCT02482168Phase 1May 1, 2015Apexigen, Inc.
Showing 14 of 14 trials
Page 1 / 1

Organizations

Research & Development (27)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Apexigen, Inc.For profit12322015
Bristol-Myers SquibbFor profit3022017
National Cancer Institute (NCI)Government2012018
Yale UniversityAcademic/Hospital2212018
A Kids Brain Tumor CureAcademic/Hospital1012018
American Lebanese Syrian Associated CharitiesAcademic/Hospital1012018
Arcus Biosciences, Inc.For profit1012022
Cancer Research InstituteAcademic/Hospital1012017
Central and Eastern European Oncology GroupAcademic/Hospital1012023
Columbia UniversityAcademic/Hospital1112019
GSO Global Clinical Research BVAcademic/Hospital1012023
Harvard UniversityAcademic/Hospital1112022
Katholieke Universiteit LeuvenAcademic/Hospital1012023
Lustgarten FoundationAcademic/Hospital1012022
Memorial Sloan-Kettering Cancer CenterAcademic/Hospital1012018
Neon TherapeuticsFor profit1112018
Nordic Society for Gynaecologic OncologyAcademic/Hospital1012023
Nordic Society of Gynaecological Oncology - Clinical Trials UnitAcademic/Hospital1112023
Pediatric Brain Tumor ConsortiumAcademic/Hospital1112018
Solving Kids’ CancerAcademic/Hospital1012018
27 organizations
Page 1 / 2